-
Industry analysts are skeptical that Federal Trade Commission Chair Lina Khan can win her first fight against a drug industry merger. It will be reviewed by a judge appointed by President Donald Trump.
-
Florida was among eight states that had sizeable decreases after reporting some of the highest overdose death rates. But experts caution that overdose deaths could rise again due to things like scaling back telehealth services.
-
As marijuana has become far more mainstream, potent, and sometimes dangerous, uneven regulation at the state and federal levels leaves consumers at risk.
-
Drug shortages are growing in the United States, and experts see no clear path to resolving them. For patients, that could mean more treatment delays, medication switches and other hassles filling a prescription.
-
At a Sarasota news conference, Attorney General Ashley Moody says xylazine is being mixed with other, more common illegal drugs, and being sold to unsuspecting users.
-
Reliance on foreign manufacturers is the top reason the U.S. struggles to head off shortages, says Sen. Gary Peters, a Michigan Democrat who chairs the Homeland security committee.
-
The funds will help to implement strategies and expand programs for treatment, education and support in Florida as well as establish the DCF Office of Opioid Recovery.
-
The veterinary tranquilizer xylazine, the choice du jour of local drug dealers to cut fentanyl, leads to necrotic ulcers and leaves street medics and physicians confused about how best to deal with this wave of the opioid crisis.
-
Private equity groups are cashing in on rising rates of alcohol and drug addiction in the U.S. But they aren’t necessarily investing in centers with the best treatment standards, and they often cut extra services.
-
Xylazine, an animal tranquilizer, is increasingly finding its way into street drugs across the country. Analysts at New Hampshire's state crime lab estimate they’re finding it in about 15% of the fentanyl they test.